Everyone should just relax! We all entered this as a speculative stock based on the payoff if DXB-200 is a blockbuster in the CBD market, amongst other minor things like the success of the Receptor-HIT platform.
If the Phase 2 results go as planned, DXB-200 will be clinically better than Retrophin's Sparsentan (currently with its nose in the lead) and also the newcomer ChemoCentryx's candidate for reducing proteinuria...and we'll all be laughing all the way to the bank!
Don't start getting shaky hands now @Prestonian...
Everyone should just relax! We all entered this as a speculative...
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
0.035(6.67%) |
Mkt cap ! $310.8M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 57.3¢ | 50.5¢ | $2.179M | 3.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30558 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |